Program Faculty

Sponsorship and CME Credit

CME Activity Assessment and Evaluation

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors

Her2-Targeted Therapies in Non–Small Cell Lung Cancer

Genomic Approaches to Lung Cancer

“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation

Mouse Models of Lung Cancer

Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

Strategies to Enhance Epidermal Growth Factor Inhibition: Targeting the Mevalonate Pathway

The Evolving Role of Cetuximab in Non–Small Cell Lung Cancer

Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer

Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition

Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer